Cancer news and cancer widget

Reuters - Oxford BioMedica said on Friday a cross-trial analysis of its experimental drug TroVax in colorectal, renal and prostate cancer showed a positive correlation between immune response and patient survival.

Nektar Therapeutics (Nasdaq: NKTR) announced that positive preclinical data for NKTR-105 (PEG-docetaxel) was presented at the 2008 EORTC-NCI-AACR (European Organization for Research and Treatment of cancer-National cancer Institute-American Association for Cancer Research) Symposium on Molecular Targets and Cancer Therapeutics being held in Geneva, Switzerland.

Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, presented positive data from a Phase 1 clinical trial of carfilzomib (PR-171) in patients with advanced solid tumors at the 20th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland.

Aurora inhibitors play a key role in cell duplication and are implicated in both the onset and progression of numerous types of tumour. A lecture focusing on Aurora kinase inhibitors will be presented today by Dr. Bernard Laffranchi during the 20th EORTC-NCI-AACR Symposium "Molecular Targets and cancer Therapeutics" organised from 21st to 24th October 2008 in Geneva.

Analysis of data from several phase I and II clinical trials of a new cancer vaccine has shown it is capable of eliciting an immune response in most patients with bowel, kidney and prostate cancer, and that it may provide clinical benefit.

In 2007, according to the National cancer Institute, an estimated 67,100 new cases of bladder cancer will be diagnosed in the United States and 13,750 people will die of the disease. For most men suffering from invasive bladder cancer, the most serious kind, treatment typically involves open surgery to remove the bladder as well as the nearby prostate and reconstruction of an ileum conduit or neobladder to divert urine.

Moffitt cancer Center will host the second biennial Latinos y el cancer Educational Symposium November 8 from 9:30 a.m. to 2 p.m. in the Vincent A. Stabile Research Building, 12902 Magnolia Drive The event is free and open to the public and will be conducted entirely in Spanish.

SuperGen, Inc. (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today presented data on MP-470, its lead product candidate, and four additional posters, at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer. This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems.

(American Association for cancer Research) Frank L. Meyskens, Jr., M.D., one of the "fathers" of the field of cancer chemoprevention, has been selected to recieve the seventh annual American Association for Cancer Research Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research.